Pliant Therapeutics, Inc. (PLRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Pliant Therapeutics reported revenue of $0. Net income was -$149.3M, or -$2.43 per diluted share. Operating activities generated -$128.3M of cash, leaving -$128.7M of free cash flow. At fiscal year end, Pliant Therapeutics held $225.2M in total assets against $44.0M in total liabilities, including $45.4M of cash and equivalents.
Open the full interactive Pliant Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Pliant Therapeutics Key Stats
| Share Price | $0.97 |
|---|---|
| Market Cap | $59.9M |
| 52-Week Range | $0.97 – $1.87 |
| Shares Outstanding | 61.9 million (basic, 2026 Q2) |
Pliant Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $41.8M | $7.6M | $9.7M | $1.6M | $0 | $0 |
| Operating Income | -$41.6M | -$97.5M | -$127.2M | -$184.1M | -$228.4M | -$156.4M |
| Pre-Tax Income | -$41.5M | -$97.3M | -$123.3M | -$161.3M | -$210.3M | -$149.3M |
| Income Tax | $0 | — | $0 | $0 | $0 | $0 |
| Net Income | -$41.5M | -$97.3M | -$123.3M | -$161.3M | -$210.3M | -$149.3M |
| Diluted EPS | -$1.95 | -$2.71 | -$2.94 | -$2.75 | -$3.47 | -$2.43 |
Pliant Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$26.3M | -$23.6M | -$20.0M | -$22.4M |
| Diluted EPS | -$0.43 | -$0.38 | -$0.32 | -$0.36 |
Pliant Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.9M | $51.7M | $33.7M | $63.2M | $71.2M | $45.4M |
| Current Assets | $290.8M | $209.4M | $340.3M | $505.5M | $362.3M | $196.4M |
| Total Assets | $295.5M | $221.2M | $350.6M | $512.2M | $396.9M | $225.2M |
| Current Liabilities | $11.6M | $16.8M | $23.9M | $28.5M | $33.2M | $16.4M |
| Total Long-Term Debt | — | — | $9.9M | $10.1M | $30.2M | — |
| Total Liabilities | $12.5M | $22.2M | $37.3M | $38.6M | $92.9M | $44.0M |
| Shareholders' Equity | $283.1M | $199.1M | $313.3M | $473.6M | $304.1M | $181.2M |
Pliant Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$37.3M | -$75.4M | -$94.6M | -$116.4M | -$155.5M | -$128.3M |
| Cash From Investing | -$210.9M | $73.7M | -$150.2M | -$127.0M | $140.3M | $134.3M |
| Cash From Financing | $213.2M | $2.5M | $226.9M | $274.4M | $23.1M | -$31.7M |
| Free Cash Flow | -$38.8M | -$77.4M | -$96.4M | -$117.3M | -$159.4M | -$128.7M |
Figures from Pliant Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Pliant Therapeutics financials page for every line item.
Pliant Therapeutics Company Profile
| Ticker | PLRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001746473 |
Frequently Asked Questions
What was Pliant Therapeutics' revenue in fiscal 2025?
Pliant Therapeutics (PLRX) reported revenue of $0 for fiscal 2025.
What is Pliant Therapeutics' annual revenue history?
Pliant Therapeutics' annual revenue by fiscal year: 2020: $41.8M; 2021: $7.6M; 2022: $9.7M; 2023: $1.6M; 2024: $0; 2025: $0.
What was Pliant Therapeutics' net income in fiscal 2025?
Pliant Therapeutics reported net income of -$149.3M for fiscal 2025.
What was Pliant Therapeutics' earnings per share (EPS) in fiscal 2025?
Pliant Therapeutics' diluted EPS was -$2.43 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Pliant Therapeutics generate in fiscal 2025?
Pliant Therapeutics generated -$128.7M of free cash flow in fiscal 2025.
What was Pliant Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Pliant Therapeutics reported revenue of $0.
How many shares of Pliant Therapeutics are outstanding?
Pliant Therapeutics reported a weighted average of 61.9 million basic shares outstanding in 2026 Q2.
What is Pliant Therapeutics' market cap?
Based on its latest closing price, Pliant Therapeutics (PLRX) has a market capitalization of about $59.9M.
When does Pliant Therapeutics' fiscal year end?
Pliant Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Pliant Therapeutics headquartered?
Pliant Therapeutics lists its business address in South San Francisco, California in its SEC filings.